IOncology

The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25, showcasing the latest advances in gastrointestinal cancer research and treatment strategies. One of the most notable studies was the BREAKWATER trial (Abstract #16), which focused on BRAF V600E-mutant metastatic colorectal cancer (mCRC). This study demonstrated a significant improvement in response rates and durable efficacy, positioning EC + FOLFOX as a promising first-line treatment option for this high-risk patient group. The findings also provide further evidence for the role of precision medicine in mCRC, reinforcing the need to integrate targeted therapy into earlier treatment settings.

The Opening Session & 2025 TAT Honorary Award on March 3 set the stage for this year’s Targeted Anticancer Therapies Congress in Paris. Elena Garralda Cabanas, Cristian Massacesi, M.D., and…

Editor's Note: Nectin-4 has emerged as a highly expressed adhesion molecule in various solid tumors, becoming a popular target in recent research. 9MW2821, developed using an internationally leading ADC development…

Hepatocellular carcinoma (HCC), one of the most lethal tumors globally, has long been a research hotspot due to its complex pathogenesis involving interactions between genetics, metabolism, and viral infections. Recently, at the 2025 EASL Liver Cancer Summit held in Paris, France, a study by Professor Mohamed Abdel Samie's team from the Department of Hepatology and Gastroenterology at the National Liver Institute, Menoufia University, Egypt, revealed the crucial role of the HNF1A genotype in HCC risk. Oncology Frontier invited Professor Mohamed Abdel Samie to discuss the potential value of this gene in HCC screening and the impact of metabolic factors. We look forward to future personalized treatment strategies targeting specific genotypes bringing new breakthroughs in the prevention and treatment of HCC.

Editor's Note: The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. At this conference, two studies from Professor Xichun Hu’s team at Fudan University Shanghai Cancer Hospital…

CheckMate 649 is the first global Phase III trial to successfully evaluate a first-line immunotherapy regimen (nivolumab + chemotherapy) for advanced gastric cancer. The study’s primary results were first unveiled at the 2020 European Society for Medical Oncology (ESMO) Congress, and the pre-specified China subgroup data were presented for the first time at the 2021 American Association for Cancer Research (AACR) meeting. The findings demonstrated even greater benefits in Chinese patients compared to the global population, generating significant academic interest and establishing first-line immunotherapy plus chemotherapy as the standard of care for advanced gastric cancer in China. Today, nivolumab in combination with chemotherapy has been approved as a first-line treatment for advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC), and esophageal adenocarcinoma (EAC) in more than 50 countries, including the United States and China.

Editor's Note: The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. At this conference, two studies from Professor Xichun Hu’s team at Fudan University Shanghai Cancer Hospital…